Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency

被引:42
作者
Bernspang, Elisabeth
Sveger, Tomas
Piitulainen, Eeva
机构
[1] Lund Univ, Univ Hosp, Dept Resp Med, SE-20502 Malmo, Sweden
[2] Lund Univ, Univ Hosp, Dept Clin Sci Paediat, SE-20502 Malmo, Sweden
关键词
lung function; COPD; alphal-antitrypsin deficiency; neonatal screening; respiratory symptom;
D O I
10.1016/j.rmed.2007.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Individuals with severe alpha-1-antitrypsin (AAT) deficiency have a well-known risk of developing emphysema but it is not known at which age the first symptoms occur and lung function declines. The aim of this study was to examine the prevalence of smoking, respiratory symptoms and lung function at the age of 30 in AAT-deficient individuals (PiZ and PiSZ) identified by neonatal screening. Material and methods: One hundred and seven PiZ, 45 PiSZ and 197 control subjects (PiMM) filled in a questionnaire regarding smoking habits and symptoms. Ninety PiZ, 40 PiSZ and 84 control subjects underwent spirometry including FEV1 and FVC. Results: Twenty-one percent of PiZ, 23% of PiSZ and 34% of PiMM subjects had smoked at some time (p < 0.05). Sixty-five percent of PiZ, 55% of PiSZ and 35% of PiMM ever-smokers reported shortness of breath on exertion (p < 0.05 PiZ vs PiMM). The mean FEV1, was 101% predicted (95% CI 98-104) in PiZ, 101% predicted (95% CI 97-106) in PISZ, and 96% predicted (95% 93-98) in PiMM individuals (p < 0.05). There was no difference in mean FEV1 when comparing ever- and neversmokers in the different Pi groups separately. Conclusion: At the age of 30, the AAT-deficient individuals in this cohort report more symptoms than the control subjects. Smoking is less common in the cohort compared to controls. Their lung function is normal. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1971 / 1976
页数:6
相关论文
共 24 条
[2]  
BERGLUND E, 1963, ACTA MED SCAND, V173, P185
[3]   Habits of life and health [J].
Bostrom, Gunnel .
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2006, 34 :199-228
[4]   THE EUROPEAN-COMMUNITY-RESPIRATORY-HEALTH-SURVEY [J].
BURNEY, PGJ ;
LUCZYNSKA, C ;
CHINN, S ;
JARVIS, D ;
VERMEIRE, P ;
DAHL, R ;
NIELSEN, N ;
MAGNUSSEN, H ;
WICHMANN, H ;
PAPAGEORGIOU, N ;
ANTO, J ;
CAPELASTEGUI, A ;
CASTILLO, J ;
MALDONADO, J ;
MORATALLA, J ;
QUIROS, R ;
BOUSQUET, J ;
NEUKIRCH, F ;
PIN, I ;
TAYTARD, A ;
TECULESCU, D ;
PRICHARD, J ;
BUGIANI, M ;
DEMARCO, R ;
CASCIO, VL ;
RIJCKEN, B ;
AVILA, R ;
LOUREIRO, C ;
MARQUES, A ;
BURR, M ;
HALL, R ;
HARRISON, B ;
STARK, J ;
FLOREY, C ;
POPP, W ;
GISLASON, T ;
GULSVIK, A ;
ACKERMANNLIEBRICH, U ;
LINDHOLM, N ;
BOMAN, G ;
ROSENHALL, L ;
AITKHALED, N ;
ABRAMSON, M ;
MANFREDA, J ;
CHOWGULE, R ;
CRANE, J ;
STEPANOV, I ;
BUIST, S .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (05) :954-960
[5]   The protease inhibitor PI*S allele and COPD: a meta-analysis [J].
Dahl, M ;
Hersh, CP ;
Ly, NP ;
Berkey, CS ;
Silverman, E ;
Nordestgaard, BG .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (01) :67-76
[6]   RISK OF CIRRHOSIS AND PRIMARY LIVER-CANCER IN ALPHA-1-ANTITRYPSIN DEFICIENCY [J].
ERIKSSON, S ;
CARLSON, J ;
VELEZ, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (12) :736-739
[7]  
FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1
[8]   NATURAL-HISTORY OF CHRONIC AIR-FLOW OBSTRUCTION [J].
FLETCHER, C ;
PETO, R .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 1 (6077) :1645-1648
[9]   NATURAL-HISTORY AND LIFE EXPECTANCY IN SEVERE ALPHA1-ANTITRYPSIN DEFICIENCY, PIZ [J].
LARSSON, C .
ACTA MEDICA SCANDINAVICA, 1978, 204 (05) :345-351
[10]   Smoking, respiratory symptoms, and diseases [J].
Lindström, M ;
Kotaniemi, J ;
Jönsson, E ;
Lundbäck, B .
CHEST, 2001, 119 (03) :852-861